| FDP(s) | 1) Fibrinolytic split Products(= FSP) 2) Fibrinogen Degradation Products |
|---|---|
| FSP | familial spastic paraplegia; fibrin split products; fibrinogen split products; fine suspended partic... |
| CGRPs | Calcitonin Gene-Related Products |
| CPSC | congenital paucity of secondary synaptic clefts [syndrome]; Consumer Products Safety Commission |
| ERPC | evacuation of retained products of conception |
| AGE | Advanced Glycation End Products |
|---|---|
| AGE | Advanced Glycosylated End-products |
| CPMP | Committee for Proprietary Medicinal Products |
| DPC | Diagnostic Products Corporation |
| DBP | Disinfection by-products |
| orphan products | Drugs, biologicals, and medical devices (including diagnostic in vitro tests) that may be useful in common or rare diseases but which are not considered commercially viable. Synonym: orphan drugs. (05 Mar 2000) |
|---|
| respiratory enteric orphan virus | A nonenveloped icosahedral virus whose genome consists of double stranded RNA, belonging to the family Reoviridae, frequently found in both the respiratory and enteric tract. Synonym: REO virus. (05 Mar 2000) |
|---|---|
| chicken embryo lethal orphan virus | <virology> A virus with characteristics of adenovirus, and similar to quail bronchitis virus. Synonym: chicken embryo lethal orphan virus. (05 Mar 2000) |
| orphan | See: orphan products. Origin: G. Orphanos (05 Mar 2000) |
| orphan disease | A disease for which no treatment has been developed because of its rarity (affecting no more than 200,000 persons in the U.S.). See: orphan products. (05 Mar 2000) |
| orphan drug | A pharmaceutical that has been abandoned or neglected during its development because it is seen as having only a limited potential for profit. Often a drug which only has a limited target population or which treats a rare disease, thus limiting its financial potential. (09 Oct 1997) |
| orphan drug act | Law giving incentives to companies developing a drug for a rare disease. The act gives the developer of the first drug of any one type a 7-year exclusive right to market the new drug. (14 Nov 1997) |
| orphan drug production | Production of drugs or biologicals which are unlikely to be manufactured by private industry unless special incentives are provided by others. (12 Dec 1998) |
| orphan drugs | Drugs, biologicals, and medical devices (including diagnostic in vitro tests) that may be useful in common or rare diseases but which are not considered commercially viable. Synonym: orphan drugs. (05 Mar 2000) |
| orphan virus | <virology> A virus that has not yet beenclassified and linked to a particular disease. (09 Oct 1997) |
| orphan viruses | Virus's, such as the enteric orphan virus's, which when originally found were not specifically associated with disease; a number of these have since been shown to be pathogenic. (05 Mar 2000) |
| enteric cytopathogenic bovine orphan virus | Former name for early isolates of bovine enteroviruses. Synonym: enteric cytopathogenic bovine orphan virus. (05 Mar 2000) |
| enteric cytopathogenic human orphan virus | eCHO virus |
| enteric cytopathogenic monkey orphan virus | Simian picornavirus recovered from monkey kidney cells and stools. Synonym: enteric cytopathogenic monkey orphan virus. (05 Mar 2000) |
| enteric cytopathogenic swine orphan virus | A picornavirus isolated from outbreaks of enteritis in swine, but not known to be a natural pathogen. Synonym: enteric cytopathogenic swine orphan virus. (05 Mar 2000) |
| enteric orphan viruses | Enteroviruses isolated from humans and other animals, "orphan" implying lack of known association with disease when isolated; many virus's of the group are now known to be pathogenic; they include ECBO viruses, ECHO viruses, and ECSO viruses. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|